N-Methyl-4-piperidinol - CAS 106-52-5
Catalog: |
BB001887 |
Product Name: |
N-Methyl-4-piperidinol |
CAS: |
106-52-5 |
Synonyms: |
1-methylpiperidin-4-ol |
IUPAC Name: | 1-methylpiperidin-4-ol |
Description: | N-Methyl-4-piperidinol (CAS# 106-52-5) is a useful research chemical. |
Molecular Weight: | 115.17 |
Molecular Formula: | C6H13NO |
Canonical SMILES: | CN1CCC(CC1)O |
InChI: | InChI=1S/C6H13NO/c1-7-4-2-6(8)3-5-7/h6,8H,2-5H2,1H3 |
InChI Key: | BAUWRHPMUVYFOD-UHFFFAOYSA-N |
Boiling Point: | 200 °C |
Purity: | 95+ % |
Density: | 1.005 g/cm3 |
Storage: | Inert atmosphere, 2-8 °C |
MDL: | MFCD00006500 |
LogP: | 0.01080 |
GHS Hazard Statement: | H315 (92.16%): Causes skin irritation [Warning Skin corrosion/irritation] |
Precautionary Statement: | P261, P264, P271, P280, P302+P352, P304+P340, P305+P351+P338, P310, P312, P321, P332+P313, P337+P313, P362, P403+P233, P405, and P501 |
Signal Word: | Danger |
Publication Number | Title | Priority Date |
CN-113097551-A | Preparation method of siloxane grafted piperidine type polyphenyl ether anion exchange membrane | 20210323 |
CN-112430342-A | Electrolyte ion exchange membrane for fuel cell and preparation method thereof | 20201130 |
KR-20200041852-A | Mollugin derivatives, and pharmaceutical composition for preventing or treating inflammatory bowel disease comprising the same | 20200413 |
KR-102223885-B1 | Mollugin derivatives, and pharmaceutical composition for preventing or treating inflammatory bowel disease comprising the same | 20200413 |
WO-2021207530-A1 | Compounds and methods for modulating splicing | 20200408 |
PMID | Publication Date | Title | Journal |
22050275 | 20111201 | Characterisation of Plasmodium falciparum aspartic protease inhibition by piperidine derivatives | Natural product research |
21721537 | 20110811 | Influence of structural variations in cationic and anionic moieties on the polarity of ionic liquids | The journal of physical chemistry. B |
11176278 | 20010201 | Radiolabeled cholinesterase substrates: in vitro methods for determining structure-activity relationships and identification of a positron emission tomography radiopharmaceutical for in vivo measurement of butyrylcholinesterase activity | Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism |
Complexity: | 66.9 |
Compound Is Canonicalized: | Yes |
Covalently-Bonded Unit Count: | 1 |
Defined Atom Stereocenter Count: | 0 |
Defined Bond Stereocenter Count: | 0 |
Exact Mass: | 115.099714038 |
Formal Charge: | 0 |
Heavy Atom Count: | 8 |
Hydrogen Bond Acceptor Count: | 2 |
Hydrogen Bond Donor Count: | 1 |
Isotope Atom Count: | 0 |
Monoisotopic Mass: | 115.099714038 |
Rotatable Bond Count: | 0 |
Topological Polar Surface Area: | 23.5 Å2 |
Undefined Atom Stereocenter Count: | 0 |
Undefined Bond Stereocenter Count: | 0 |
XLogP3: | 0.1 |
Online Inquiry
Customer Support
Customer Centered
Related Functional Groups
Piperidines
Customers Also Viewed
INDUSTRY LEADERS TRUST OUR PRODUCTS